Fintel reports that on January 7, 2026, UBS initiated coverage of Allogene Therapeutics (NasdaqGS:ALLO) with a Buy recommendation.
Analyst Price Forecast Suggests 446.89% Upside
As of December 21, 2025, the average one-year price target for Allogene Therapeutics is $7.71/share. The forecasts range from a low of $1.62 to a high of $14.70. The average price target represents an increase of 446.89% from its latest reported closing price of $1.41 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Allogene Therapeutics is 2,474MM, an increase of ∞%. The projected annual non-GAAP EPS is -2.32.
What is the Fund Sentiment?
There are 308 funds or institutions reporting positions in Allogene Therapeutics. This is an decrease of 9 owner(s) or 2.84% in the last quarter. Average portfolio weight of all funds dedicated to ALLO is 0.07%, an increase of 29.12%. Total shares owned by institutions decreased in the last three months by 11.17% to 186,926K shares. 
The put/call ratio of ALLO is 0.09, indicating a bullish outlook.
What are Other Shareholders Doing?
Pfizer holds 22,032K shares representing 9.80% ownership of the company. No change in the last quarter.
Tpg Gp A holds 18,716K shares representing 8.33% ownership of the company. No change in the last quarter.
Citadel Advisors holds 13,972K shares representing 6.22% ownership of the company. In its prior filing, the firm reported owning 10,253K shares , representing an increase of 26.62%. The firm increased its portfolio allocation in ALLO by 31.06% over the last quarter.
SMCWX - SMALLCAP WORLD FUND INC holds 11,312K shares representing 5.03% ownership of the company. In its prior filing, the firm reported owning 12,265K shares , representing a decrease of 8.43%. The firm decreased its portfolio allocation in ALLO by 37.57% over the last quarter.
Primecap Management holds 7,079K shares representing 3.15% ownership of the company. In its prior filing, the firm reported owning 5,719K shares , representing an increase of 19.21%. The firm increased its portfolio allocation in ALLO by 31.28% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
